These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. Melphalan perfusion in treatment of melanoma. Jönsson PE Br J Surg; 1981 May; 68(5):369-70. PubMed ID: 7225765 [No Abstract] [Full Text] [Related]
27. Randomized multicenter trial of hyperthermic isolated limb perfusion with melphalan alone compared with melphalan plus tumor necrosis factor: American College of Surgeons Oncology Group Trial Z0020. Cornett WR; McCall LM; Petersen RP; Ross MI; Briele HA; Noyes RD; Sussman JJ; Kraybill WG; Kane JM; Alexander HR; Lee JE; Mansfield PF; Pingpank JF; Winchester DJ; White RL; Chadaram V; Herndon JE; Fraker DL; Tyler DS; J Clin Oncol; 2006 Sep; 24(25):4196-201. PubMed ID: 16943537 [TBL] [Abstract][Full Text] [Related]
28. Factors predictive of acute regional toxicity after isolated limb infusion with melphalan and actinomycin D in melanoma patients. Kroon HM; Moncrieff M; Kam PC; Thompson JF Ann Surg Oncol; 2009 May; 16(5):1184-92. PubMed ID: 19224289 [TBL] [Abstract][Full Text] [Related]
29. [Regional perfusion treatment in primary malignant melanomas of the extremities. (Microstage IV/V according to Clark and tumor thickness over 1.5 mm)]. Schraffordt Koops H; Oldhoff J Hautarzt; 1982 Sep; 33(9):506-10. PubMed ID: 7174325 [TBL] [Abstract][Full Text] [Related]
30. [Regional hyperthermic perfusion has impressive effect on manifest malignant melanoma]. Hafström L Lakartidningen; 1992 Sep; 89(39):3189-90. PubMed ID: 1405932 [No Abstract] [Full Text] [Related]
31. A multi-institutional experience of isolated limb infusion: defining response and toxicity in the US. Beasley GM; Caudle A; Petersen RP; McMahon NS; Padussis J; Mosca PJ; Zager JS; Hochwald SN; Grobmyer SR; Delman KA; Andtbacka RH; Noyes RD; Kane JM; Seigler H; Pruitt SK; Ross MI; Tyler DS J Am Coll Surg; 2009 May; 208(5):706-15; discussion 715-7. PubMed ID: 19476821 [TBL] [Abstract][Full Text] [Related]
32. [Surgical treatment and regional chemotherapy in melanoma of the extremities]. Henneking K; Binder J; Weyers W; Schwemmle K Chirurg; 1993 Feb; 64(2):134-8. PubMed ID: 8462350 [TBL] [Abstract][Full Text] [Related]
34. Eleven years' experience with hyperthermic perfusion for melanoma of the extremities. Stehlin JS; Giovanella BC; de Ipolyi PD; Anderson RF World J Surg; 1979 Jul; 3(3):305-7. PubMed ID: 473783 [No Abstract] [Full Text] [Related]
35. Repeat isolated limb perfusion with melphalan for recurrent melanoma of the limbs. Klop WM; Vrouenraets BC; van Geel BN; Eggermont AM; Klaase JM; Nieweg OE; Kroon BB J Am Coll Surg; 1996 Jun; 182(6):467-72. PubMed ID: 8646345 [TBL] [Abstract][Full Text] [Related]
37. [Isolated hyperthermic perfusion of the extremities with cytostatic agents. A method of treatment in malignant melanoma and soft tissue sarcoma]. Kettelhack C; Schlag P Dtsch Krankenpflegez; 1989 Sep; 42(9):597-601. PubMed ID: 2518209 [No Abstract] [Full Text] [Related]